Skip to main content

Table 2 Primary and secondary endpoints

From: Protocol for a prospective randomized controlled trial of recipient remote ischaemic preconditioning in orthotopic liver transplantation (RIPCOLT trial)

Primary endpoints

Ability to recruit patients to the trial

Feasibility of performing RIPC in liver transplant recipients

Safety of RIPC in liver transplant recipients

Secondary endpoints

AST levels on the third post-operative day [30]

Incidence of acute kidney injury and need for renal replacement therapy

Length of stay in intensive care and total hospital stay

Incidence of vascular thrombotic events

Incidence of biliary complications

Incidence of post-operative infections

Incidence of acute rejection in the first months post transplantation

Circulating cytokine levels 2 h post reperfusion of the liver graft

T cell accumulation and activation in the liver 2 h post reperfusion

Urinary and serum NGAL levels 2 h post reperfusion